Huveaux PLC
26 June 2007
26 June 2006
HUVEAUX PLC
TRADING UPDATE
Huveaux is today making the following trading update ahead of its half-year
results announcement which is expected to be made on 26 July.
While EBITDA for 2007 is expected to slightly exceed the level achieved in 2006,
this is below current market expectations.
Healthcare Division
Our Healthcare Division in France has seen a significant drop in sales revenue
as compared to the first half of 2006. This is as a direct result of
pharmaceutical companies cutting their advertising budgets across the board in
response to the sharp rise in generic drugs. The revenues from our Continuing
Medical Education accredited publications and other product offerings have
started to flow through, but these have not been sufficient to offset the impact
from the decline in pharmaceutical advertising. Accordingly, the outlook for the
year is that sales and EBITDA of the Healthcare Division will be significantly
lower than in 2006.
Nevertheless, the expected performance of the Healthcare Division in 2007 will
still give at least a 15% pre-tax return on the original cost of acquisition -
significantly in excess of our cost of capital.
Political Division
The Political Division continues to make progress with good organic revenue
growth. Its market-leading positions in London, Paris and Brussels continue to
be strengthened and the outlook for the year remains very positive.
Learning Division
This division has been impacted by training budget cuts in Government
Departments during the first half of 2007. Sales have started to recover during
the past few weeks and the outlook is for a strong second half performance.
Nevertheless, for 2007 as a whole, sales and EBITDA are likely to be lower than
in 2006.
Education Division
The Education Division is making very good progress with strong organic growth
in both sales and EBITDA. Under Huveaux's new ownership, the historic revenue
decline at Letts has been reversed and Lonsdale's sales are up significantly on
last year, including an encouraging increase in Science curriculum sales. Leckie
& Leckie has also produced an outstanding performance with record profits and
increased market share driven by an expanded portfolio. The 2007 outlook for the
Education Division is therefore excellent.
The Company continues to make strategic progress in key areas and is strongly
committed to increasing shareholder value. Accordingly, the complementary
acquisition of the European Public Affairs Directory was completed in May and
our small contract publishing business in the Healthcare Division was sold in
June. A review of our paper and print costs is also likely to have a beneficial
effect on the 2008 results.
Management has initiated a recovery programme and further details will be
included in the half-year results announcement.
END
For further information, please contact:
Huveaux
John van Kuffeler
Executive Chairman 020 7245 0270
Gerry Murray
Chief Executive Officer
Dan O'Brien
Group Finance Director
Finsbury
James Leviton 020 7251 3801
Don Hunter
About Huveaux:
Huveaux PLC is a public limited company listed on the Alternative Investment
Market (ticker HVX.L).
The Company was formed in 2001 with the objective of building a substantial,
high-quality media group. Huveaux has completed and successfully integrated 13
acquisitions over the past six years and employs more than 500 staff in London,
Paris, Brussels, Edinburgh and four other UK regional offices.
The Group now consists of four Divisions, each of which has strong brands and
market leading positions:
Political Division
The market leader in political business-to-business publishing in the UK and EU,
serving both the political and public affairs communities. The Division
comprises Dods Parliamentary Companion, The House Magazine, Epolitix.com and
numerous other political magazines, reference books, monitoring products and
revenue-generating websites as well as events, awards and recruitment services.
Healthcare Division
One of the leading providers of specialist B2B publications and online education
for the medical sector in France. The Division comprises Panorama du Medecin, a
leading weekly magazine for French doctors, Le Concours Medical and La Revue du
Praticien, market-leading Continuing Medical Education magazines, Egora.fr, the
leading medical information website, a medical conference business and a number
of other magazines and reference materials.
Learning Division
A leading provider of resources to learning communities in the UK, including
e-learning solutions for the public and private sector and blended learning
solutions, seminars and events for the political, public affairs and training
markets. The Division comprises Epic, the UK market leader in e-learning, The TJ
magazine and the highly acclaimed Westminster Explained conferences and seminars
business.
Education Division (established 1 January 2007)
The leading supplier of study aids and revision guides in the UK, with full
product coverage across all subjects and stages of the entire curriculum in UK
schools. The Division comprises Lonsdale, Letts Educational and Leckie & Leckie.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.